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HIV-1 assembly depends on its structural protein,
Gag, which after synthesis on ribosomes, traffics to
the late endosome/plasma membrane, associates
with HIV Env glycoprotein, and forms infectious
virions. While Env and Gag migrate to lipid microdo-
mains, their stoichiometry and specificity of interac-
tion are unknown. Pseudotyped viral particles can
be made with one viral core surrounded by heterolo-
gous envelope proteins. Taking advantage of this
property, we analyzed the association of HIV Env
and Ebola glycoprotein (GP), with HIV-1 Gag
coexpressed in the same cell. Though both viral
glycoproteins were expressed, each associated in-
dependently with Gag, giving rise to distinct virion
populations, each with a single glycoprotein type.
Confocal imaging demonstrated that Env and GP
localized to distinct lipid raft microdomains within
the same cell where they associated with different
virions. Thus, a single Gag particle associates ‘‘quan-
tally’’ with one lipid raft, containing homogeneous
trimeric viral envelope proteins, to assemble func-
tional virions.
INTRODUCTION
The assembly of HIV-1 is dependent on its major structural pro-
tein, Gag. The Gag precursor protein, Pr55 Gag, is synthesized
on free cytosolic ribosomes and traffics to the late endosome/
plasma membrane where it associates with the viral Env glyco-
protein (Freed, 1998). While Gag has been detected in raft-like
membrane microdomains (Lindwasser and Resh, 2001; Ono
and Freed, 2001) and thematrix (MA) domain of HIV-1 Gag binds
specifically to a plasma membrane-associated phospholipid,
PI(4,5)P2 (Ono et al., 2004), the process by which Gag particles
associate specifically with viral glycoproteins is not understood.
In HIV-infected T cells, newly synthesized Env transits from the
ER to theGolgi where the newly addedN-linked polysaccharides
are modified. The subsequent trafficking of Env and its targeting
to Gag is not completely understood. While a portion has beensuggested to transit to CTLA-4-containing secretory granules
(Miranda et al., 2002), 5%–15% of the newly synthesized
gp160 traffics directly to the cell surface (Willey et al., 1988).
Recent studies have shown that HIV-1 and Ebola virus, two
unrelated viruses, both employ Tsg101, an endosomal protein
sorting factor, for efficient budding (Martin-Serrano et al.,
2001). Furthermore, budding of both HIV-1 and Ebola virus oc-
curs through lipid rafts of the host cell plasma membrane (Bavari
et al., 2002; Rousso et al., 2000). The Ebola glycoprotein (GP) is
a typical trimeric viral spike protein with coiled coils and a fusion
domain that mediates pH-dependent virus entry into host cells.
It is generally known that pseudotyped viral particles can be
made with the core of one virus surrounded by a heterologous
envelope protein. Lentiviral vector pseudotyping has been
achieved using viral producer cells transfected with three ex-
pression plasmids: a lentiviral packaging construct encoding
HIV Gag, an envelope-encoding plasmid, and a reporter vector
expressing luciferase (Naldini et al., 1996). The use of this system
in transiently transfected 293T cells allowed production of pseu-
dotyped lentiviral vectors that could be used to study intracellu-
lar trafficking of HIV Gag and alternative envelope proteins,
specifically HIV Env and Ebola GP. Here, we used this system
to study the assortment of two distinct viral glycoproteins, syn-
thesized from a single expression vector within the same cell,
into viral particles. This analysis was performed by biochemical
analysis and immunoprecipitation of virus preparations to deter-
mine the surface expression of each glycoprotein and by confo-
cal imaging within virus producer cells and in HIV-1-infected
primary T cells. Gaining a knowledge of this process advances
a basic understanding of viral protein trafficking and HIV virion
formation at the same time that it lends insight into potential
targets of antiviral therapy and vaccine design.
RESULTS
Physical and Biochemical Characterization
of Pseudotyped Lentivirus Vectors
To examine the specificity and mechanism of HIV Gag and Env
protein association, plasmid expression vectors encoding repli-
cation-defective lentiviral vectors were prepared that could be
pseudotyped with both HIV-1 Env and Ebola GP viral glycopro-
teins. To ensure that both viral glycoproteins were synthesized
in the same cell, a single eukaryotic expression vector wasCell Host & Microbe 3, 285–292, May 2008 ª2008 Elsevier Inc. 285
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moters, and this plasmid was cotransfected along with Gag
and a luciferase reporter gene linked to a packaging sequence
that was used to quantitate infectivity. Expression of the enve-
lope proteins was first confirmed biochemically: each viral glyco-
proteinwasdetected bywestern blotting in the same fractions af-
ter buoyant density sedimentation analysis (Figures 1A and 1B),
with Env, GP, and Gag expression observed within the range of
densities expected for functional lentiviral particles (Yang et al.,
2004). Cell surface expression of both Env and GP, the viral
spikes, in the same cell was confirmed by flow cytometry
(Figure 1C; right upper panel). Their expression was comparable
to singly transfected viral spikes and was not significantly altered
when expressed with Gag (Figure 1C; fourth versus second and
third columns, and upper versus lower panels).
Functional and Immunological Analysis
of Pseudotyped Lentivirus Vectors
The functional activity of the pseudotyped lentiviral vector prep-
aration was demonstrated by its ability to transduce both an
HIV-1 target cell, theMT-2 T leukemia, as well as a cell infectable
by Ebola GP, the 786-O cell (Figure 2A). The specificity of each
singly pseudotyped lentiviral vector was confirmed by incuba-
tion of buoyant density-purified virus with specific neutralizing
antibodies known to interact with native, functional viral spikes.
The 2F5 (Muster et al., 1993) and 2G12 (Trkola et al., 1996)
monoclonal antibodies inhibited HIV lentiviral vector transduc-
tion while KZ52 (Maruyama et al., 1999) specifically reduced
Ebola vector expression from viruses made in the doubly trans-
fected (Env/GP) producer cells (Figure 2B, left, aEnv and right,
aGP); however, neither inhibited entry of the pseudotyped
vectors into the heterologous target cell (Figure 2B, left, aGP
and right, aEnv), confirming their specificity.
To determine whether entry in a population of virions pseudo-
typed with both viral glycoproteins in the same producer cell was
mediated by single or mixed spike viruses, immunodepletion
studies were performed. Neutralizing antibodies were used for
immunodepletion and immunoprecipitation studies because
they are the only ones known to react with native spike on virions.
Unexpectedly, incubation followed by precipitation with Env- or
GP-specific antibodies eliminated transduction of the relevant,
but not the heterologous, target cell population compared to
control IgG using comparable amounts of infecting vectors
(Figure 3A, left, aEnv versus aGP or IgG and right, aGP versus
aEnv or IgG), implying that the viral envelopes segregated to dis-
tinct viral particles despite the fact that both were expressed in
the same cells using the double expression vector. Immunode-
pletion studies were also performed on virions produced from
singly (Env or GP) transfected 293T cells and mixed in different
ratios. Similar patterns of infectivity and reduction after immuno-
depletion were observed with these mixed samples on the rele-
vant target cells (Figure S1 available online). Similar to vectors
from doubly transfected cells, a small amount of residual activity
remained due to incomplete depletion. This analysis confirmed
the specificity of the depletion and comparable behavior of
mixed singly pseudotyped vectors.
The presence of the relevant viral glycoproteins on separate
virions was demonstrated by biochemical analysis of lentiviral
vectors made in cells expressing both Env and GP. Band-puri-286 Cell Host & Microbe 3, 285–292, May 2008 ª2008 Elsevier Inc.fied virus was analyzed by immunoprecipitation using specific
antibodies against each protein followed by western blotting.
No Env was detected on purified virions derived from GP/Env
producer cells after immunoprecipitation with 13C6, a specific
mouse antibody against GP, while it was readily detected after
anti-Env precipitation (Figure 3B, lane 1 versus 4). Conversely,
no GP was detected on purified virions from GP/Env producer
cells after immunoprecipitation with Env antibody, while it was
readily detected after anti-GP precipitation (Figure 3B, lane 10
versus 7). Viruses immunoprecipitated with Env antibodies
showed western blot reactivity with Env antibody in the Env or
doubly-transfected producer cells (Figure 3B, lanes 4 and 6 ver-
sus 5) and those from GP- and doubly-transfected producer
cells reacted with anti-GP, but not anti-Env (Figure 3B, lanes 7,
8 versus 9), though the signals obtained from virions derived
from singly expressing producer cells were stronger than those
doubly expressing ones. When a secondary immunoprecipita-
tion was performed with the heterologous spike antibody on
the first immunodepleted supernatant, Env was detected in
Figure 1. Analysis of Buoyant Density Gradient Fractionated Env/GP
Pseudotyped Lentiviral Vectors
293T cells were transfected with the packaging vector pCMVDR8.2, pHR0-
CMV-Luciferase, as well as the Env + GP expression vector.
(A) Virus supernatant was harvested 60 hr later for buoyant density gradient
analysis.
(B) Rabbit anti-GP, anti-gp120, and anti-Gag were used for subsequent west-
ern blot detection of GP, Env, and Gag, respectively, in each fraction.
(C) Comparable expression of GP and Env was confirmed on viral producer
cells transfected singly (GP or Env) or doubly (GP/Env) with the indicated
spikes.
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19), and GP was found in Env-depleted supernatants (Figure 3B,
lanes 28). These biochemical data document the segregation of
the two viral glycoproteins to distinct virion populations, thus
complementing and confirming the functional immune precipita-
tion studies.
Segregated Localization of Envelope Proteins
in MAGI-CCR5 Cells
The ability of different viral spikes to localize specifically with
different virions was further analyzed by confocal imaging mi-
croscopy. Since the cell line 293T utilized as pseuodtyped virus
producer was not readily adherent and therefore less optimal for
confocal imaging, MAGI-CCR5 cells, a HeLa cell clone express-
ing human CD4 and CCR5, were analyzed by this technique.
These cells exhibited Env and GP expression and distribution
similar to that of the 293T cells (Figure S2) and are productively
infected by HIV. They were, therefore, also amenable to analysis
after infection with replication-competent virus.
Previous studies have shown that closely related HIV Env
glycoproteins can form mixed heterotrimers that mediate func-
tional viral entry (Yang et al., 2005b). To compare and contrast
the behavior of such homologous, mixed heterotrimers to differ-
ent viral glycoproteins that cannot form heterotrimers, two HIV
Env expression vectors were tagged with distinct epitopes, HA
andmyc, in the V1 region and analyzed for their ability to colocal-
ize in cotransfected cells. Three-dimensional visualization of
transfected MAGI-CCR5 cells revealed colocalization of HA-Env
and myc-Env (Figure 4A, left panels; Pearson’s correlation =
0.493), as would be expected from previous studies (Yang et al.,
2005b). While this correlation is highly significant, the association
of HA- and myc-Env trimers is not complete because of the
statistical nature of trimer formation, where homotrimerization
would be anticipated in approximately one-third of spikes.
Thus, the degree of colocalization seen by confocal microscopy
is within the expected range. In contrast, when cells were
cotransfected with Env and Ebola GP, these two envelope
Figure 2. Specificity of Lentiviral Vectors Determined by Inhibition
of Gene Transfer with Neutralizing Antibodies and Biochemical
Evidence of Segregation of Viral Envelopes
(A) Pseudotyped lentiviral vectors produced from single (Env or GP) or doubly
(GP/Env) transfected 293T cells infect corresponding HIV (MT2) and Ebola
(786-O) target cells. Error bars indicate standard error of the mean of at least
three independent transductions.
(B) Antibody neutralization of pseudotyped lentiviral vectors produced from
doubly transfected 293T cells and fractionated in buoyant density gradient.
For antibody neutralization, viruses were incubated at 37C for 1 hr with 2F5
and 2G12 (5 mg/ml each), or for GP with KZ52 (20 mg/ml) before infecting the
target cells.Figure 3. Evidence of Segregation in Virions Made from Producer
Cells Expressing Two Alternative Viral Spikes by Immunodepletion
and Biochemical Analyses
(A) Immunodepletion of Optiprep band-purified virions prepared from double
expression plasmid (Env/GP) with anti-Env (2F5 and 2G12) or anti-GP (KZ52)
as indicated. Error bars indicate standard error of the mean of at least three
independent transductions.
(B) Primary (lanes 1–18) and secondary immunoprecipitation (lanes 19–36) of
purified virions with heterologous antibody, anti-GP or anti-Env, respectively,
followed by western blotting for the indicated gene products (right), providing
biochemical evidence for the absence of chimeric virus. For immunodeple-
tion, virus supernatants were incubated with 2F5 and 2G12 (5 mg/ml each)
or for GP with KZ52 (20 mg/ml) at 4C for 60 min before addition of biomag-
netic particle-conjugated anti-human IgG for another 3 hr. Immune com-
plexes were held in place with a strong magnet during the removal of the virus
supernatant. Human IgG served as negative control. Immunoprecipitation of
Env containing pseudotyped lentiviral vector was performed by incubating
with human HIV Igb12 (1 mg/ml) and GP containing pseudotyped lentiviral
vector with 13C6 (1 mg/ml) at 4C for 60 min before adding protein A/G for
another 3 hr. Immune complexes were separated from the virus supernatant
by centrifugation at 4000 3 g for 3 min. Between primary and secondary im-
munoprecipitation, the virus supernatants were precleared by incubating with
protein G agarose for 3 hr before removal of the agarose beads. mAb 149,
rabbit anti-gp120, and anti-Gag (Advanced Biotechnologies, Columbia, MD)
were used for subsequent western blot detection of GP, Env, and Gag,
respectively, in each immune complex.Cell Host & Microbe 3, 285–292, May 2008 ª2008 Elsevier Inc. 287
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sites within the same cell (Figure 4A, right panels; Pearson’s
correlation=0.2633).Antibodystainingof intact versuspermea-
bilized cells had no effect on this pattern of distribution (data not
shown), andcotransfectionwithGag similarly did not alter thedis-
tribution or lack of colocalization (Figure 4B, upper- versus lower-
right panels; Figure S3). Therefore, heterologous viral envelope
proteins do not colocalize evenwhen both are synthesized simul-
taneously in the same producer cells.
Segregated Colocalization of HIV-Gag
and Envelope Proteins
To quantify the interaction of Gag with Env or GPwithin the same
cell, we examined transiently transfected MAGI-CCR5 cells for
each component by immunofluorescence and confocal imaging.
Figure 4. Confocal Microscopy of Transfected MAGI-CCR5 Cells
Revealed that GP Did Not Colocalize with Env, and This Pattern
Did Not Change in the Presence or Absence of Gag
(A) MAGI-CCR5 cells were transfected with myc- or HA-Env expression
vectors and tagged within the V1 region (see Experimental Procedures), which
showed colocalization and served as a positive control (left panels). MAGI-
CCR5 cells were transiently transfected with GP and HA-Env-expression
vectors (right panels). Immunofluorescent staining was performed 40 hr later.
Z stack sectioning of the cells was collected and analyzed by Imaris software
to obtain 3D reconstruction and colocalization statistics.
(B) MAGI-CCR5 cells were transiently transfected with Env, GP, or double
expression plasmid (Env/GP) in the presence or absence of packaging vector
pCMVDR8.2, which containsGag. Immunofluorescent stainingwas performed
40 hr later. Z stack sectioning of the cells was collected and analyzed by Imaris
software.288 Cell Host & Microbe 3, 285–292, May 2008 ª2008 Elsevier Inc.Z stack sections and the images were processed with Imaris
software (version 5.3.3; Bitplane AG, Zurich, Switzerland). Using
channel masking of contour surface objects and iso-surface
modeling, colocalization of these respective gene products
was defined. There was minimal colocalization of Gag and Env
throughout the cell (Figure 5A; Pearson’s correlation = 0.13);
however, when the analysis was limited to the plasmamembrane
region where virus assembly occurs by setting specific gating
criteria (Figure S4), the correlation coefficient between Gag
and Env increased to 0.26 (Figure 5B), suggesting that the
association was greater at the site of budding on the plasma
membrane. The cytoplasmic distribution of GP was too low to
generate a meaningful correlation with Gag, but a positive corre-
lation between GP and Gag was also evident at the plasma
membrane (Figure 5C; 0.66). Interestingly, Env and GP showed
no evidence of colocalization: the Pearson’s correlation was
close to zero both in the cytoplasm and on the membrane
(Figure 5D), indicating these two viral spike proteins segregated
to distinct sites in discrete lipid rafts. Therefore, it appeared that
each viral glycoprotein associated independently with distinct
Gag ribonucleoprotein complexes to give rise to distinct viral
particles. Finally, to confirm the distribution of Gag and Env in
HIV-infected cells, imaging was performed on MAGI-CCR5 cells
and human CD4+ T cells stimulated with anti-CD3 and
Figure 5. Lack of Colocalization of Heterologous Envelope Proteins,
Env and GP, in Producer Cells
Confocal microscopy revealed that GP did not colocalize with Env. MAGI-
CCR5 cells were transiently transfected with packaging vector pCMVDR8.2
and GP- and HIV-EnvADA-expressing vectors. Immunofluorescence staining
was performed 40 hr later. Z stack sectioning of the cells was collected and
analyzed by Imaris software to obtain iso-surface models. (A) Expanded
view of a thick section of a single cell is presented here as an iso-surfacemodel
depicting Env, GP, and Gag distribution in the vicinity of the plasma mem-
brane. (B)–(D) depict two of the three viral proteins presented in (A) for clear
visual comparisons. Descriptions of the method used to identify membrane
versus cytoplasmic proteins with Imaris software are described further in the
Experimental Procedures and Figure S4.
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producer, MAGI-CCR5, were observed in both cell types
(Figure 6A), consistent with their localization to discrete lipid
rafts. As in the viral producer cells, Gag was distributed through-
out the cell cytoplasm. Colocalization was observed in HIV-
infected primary T cells at discrete sites at the membrane similar
to the viral producer cells, where 14.2% of Env was found in
association with Gag (Figure 6B), also consistent with the find-
ings in viral producer cells.
DISCUSSION
In this study, the ability of HIV-1 Gag to associate with different
viral glycoproteins within the same cell was examined. It was
expected that a producer cell containing two viral spikes could
give rise to virions containing both viral spike glycoproteins
(Figure 7). Though the producer cell was able to generate viral
Figure 6. Distribution of Env and Gag in HIV-Infected Cells
(A) Confocal imaging confirms the expression of Env in discrete locations
intracellularly, largely separate from Gag in MAGI-CCR5 and aCD3/CD28
stimulated human CD4 lymphocytes. MAGI-CCR5 or human CD4 cells were
infected with HIV-1 89.6 and analyzed by immunofluorescent staining 48 hr
later. Approximately one percent of cells were infected by this criteria.
(B) Z stack sectioning of the cells was collected and analyzed by Imaris soft-
ware to obtain iso-surface models as in Figure 5. A thick section of a single
cell is presented here as iso-surface model for each cell type depicting Env
and Gag distribution within the cytoplasm and plasma membrane as well as
areas of colocalization.particles that incorporated each viral spike, these glycoproteins
segregated to distinct lipid raft-like microdomains and ulti-
mately separated pseudotyped lentiviral vectors (Figures 3–5).
This finding suggests that a single Gag particle associates
with one lipid raft that is homogeneous with respect to trimeric
viral envelope. This observation was made for both Ebola and
HIV glycoproteins, and we have observed it between HIV-1
Env and other viral glycoproteins as well, including HIV-1 Env
and SARS, HIV-1 Env and FeLV, and HIV-1 and MuLV (data
not shown). Previous studies have demonstrated that Envs de-
rived from closely related lentiviruses, such as HIV-1 variants or
HIV-2 and SIV, can form mixed heterotrimers (Boulay et al.,
1988; Doms et al., 1990; Yang et al., 2005a; Yang et al.,
2005b). Such heterotrimers would be expected to colocate to
the same lipid raft as confirmed here (Figure 4A, left panels),
but viral spikes from different glycoproteins did not colocalize
to the same lipid rafts (Figure 4A, right panel). These observa-
tions suggest that this association is dependent on the coiled-
coil region of the viral spike, which may also contribute to the
formation of trimeric oligomers within the lipid raft. While each
raft is homogeneous with respect to the viral spike, other host
membrane glycoproteins are not likely excluded from the raft
because many such cellular proteins are incorporated into
mature virus particles (Arthur et al., 1992).
The assembly of virus particles requires packaging of viral
proteins and RNA. For enveloped viruses like HIV and Ebola, as-
sembly and budding occurs at the plasmamembrane of infected
cells (Cimarelli and Darlix, 2002; Maruyama et al., 1999; Hartlieb
and Weissenhorn, 2006) and possibly through endosomal mem-
branes (Martin-Serrano et al., 2001; Ono and Freed, 2004; Dong
et al., 2005; Grigorov et al., 2006), though virus located at this
latter site could arise by endocytosis of recently released virus
(Jouvenet et al., 2006). In HIV-infected T cells, newly synthesized
Env transits from the ER to the Golgi, where nascent N-linked
polysaccharide side chains are modified, and the protein traffics
to the cell surface. Previous studies have shown that HIV-1, and
Figure 7. Models of Segregation of Viral Spikes with Lentiviral Ribo-
nucleoprotein Complexes
While it was expected that cells expressing two different trimeric viral spikes
could give rise to virions containing both proteins, trafficking of such spikes
to distinct lipid rafts that associate individually with Gag particles would give
rise to virions containing one or the other viral glycoprotein, a model supported
by the data in this study.Cell Host & Microbe 3, 285–292, May 2008 ª2008 Elsevier Inc. 289
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protein sorting factor, as well as other members of the ESCRT
pathway (reviewed in Goff et al., 2003; Martin-Serrano et al.,
2001) to facilitate budding of the assembled virus from cells.
Lipid rafts have been estimated at 100–200 nm in diameter
(Pike, 2003), while an HIV virion is 125 nm (Briggs et al.,
2006). These sizes, along with the finding that virions packaged
in cells contain only one of the two expressed viral glycopro-
teins, are consistent with a model in which a virion arises from
a single lipid raft domain that associates with an assembled
Gag particle.
The replication-defective pseudotyped lentiviral vectors ex-
amined here facilitate the analysis of the molecular mechanisms
of this process. It was generally known that pseudotyped viral
particles could be made with the core of one virus surrounded
by heterologous envelope proteins. But, the segregation of dif-
ferent spikes to distinct viral particles has not been previously
appreciated, and this finding was unexpected. Confocal micros-
copy revealed distinct subcellular distribution of Env, GP, and
Gag. Though at the plasma membrane, Env and GP colocalized
separately with Gag at the presumed site of budding. Further-
more, Gag expression did not alter the subcellular distribution
of envelope proteins by confocal imaging analysis (Figure 4B;
Figure S2). A similar distribution of Env or GP was observed
intracellularly in cells cotransfected with or without HIV-1 Gag.
The association of a single viral spike with each particle suggests
that the viral ribonucleoprotein complex associates with each
lipid raft. This finding could arise if Gag oligomerization occurred
prior to its association with an individual raft. Alternatively, the
interaction of Gag with its relevant viral glycoproteins on a lipid
raft may recruit additional Gagmolecules to complete the forma-
tion of a single viral particle.
A recent paper by Brass et al. (Brass et al., 2008) employed
small interfering RNA screening to identify more than 250 host
proteins implicated in HIV replication. Among them, it is interest-
ing to note that Caveolin-2 (Cav-2) is a lipid raft-associated host
protein previously shown to inhibit HIV virion production more
than 90% in 293T cells (Llano et al., 2002). This observation
raises the possibility that this caveolin-related pathway may be
involved in the segregation of viral spikes to distinct particles.
Elucidation of such mechanisms will provide further understand-
ing of this process and possible targets for antagonists of HIV
replication.
Concurrent viral infections are well documented to occur in
nature, and the ability of viral spike proteins to associate with
their cognate viral ribonucleoprotein complex is critical to the
generation of replication-competent viruses. The inclusion of
the appropriate glycoproteins and exclusion of heterologous en-
velope proteins would, in fact, be crucial for the survival of a virus
species. Here, the analysis of two envelopes expressed in a pro-
ducer cell also served to define the mechanism of viral assembly
further. The quantal nature of the spike association with Gag pro-
vides fundamental insight into the nature of HIV-1 assembly and
suggests that the virus exploits normal cellular substructures
and pathways of protein trafficking to allow its disparate compo-
nents to interact selectively and to complete assembly. Knowl-
edge of this mechanism also facilitates the development of
antagonists of HIV-1 that could inhibit productive viral replication
and lends insight into strategies for AIDS vaccine design.290 Cell Host & Microbe 3, 285–292, May 2008 ª2008 Elsevier Inc.EXPERIMENTAL PROCEDURES
Plasmid Construction
Double expression vectors were developed to express both HIV gp16089.6P
(Env) and SARS-CoV spike (S) protein (Huang et al., 2004), or Ebola GPZaireD
muc (GP) (Yang et al., 2000). S or GP was expressed under the control of an
mPGK promoter and bovine growth hormone polyadenylation expression cas-
sette, whereas Env was regulated by the RSV promoter and SV40 polyadeny-
lation sequence. Briefly, the mouse PGK promoter (McBurney et al., 1991) was
amplifiedwith the senseprimer 50-AATTTGGCCAGGTACCGAATTCTACCG
GGTAGGGGAGGCGCTT-30 andantisenseprimer 50CCTTGATATCGGTCG
AAA GGC CCG GAG ATG 30. The MscI/EcoRV fragment of mPGK was then
inserted into MscI/EcoRV-digested pVRC1012-gp145DCFIDV12 (Yang et al.,
2004), and gp145DCFIDV12 was subsequently replaced by digestion with
XbaI and treatment with Klenow, followed by BamHI digestion and insertion
with S (isolated from CMV/R-S [Huang et al., 2004] by digestion with SalI
followed by Klenow incubation, then BamHI digestion). Alternatively,
gp145DCFIDV12 was replaced by digestion with BamHI, treatment with
Klenow incubation, and then XbaI digestion and insertion with GP (isolated
from pGPDMUC [Yang et al., 2000]) by incubation with KpnI, treatment with
Klenow fragment, followed by XbaI digestion). The expression vector encoding
Env was prepared by ligating an XbaI/Klenow/BamHI fragment of Env from
plasmid pVRC1012-gp160(89.6P) (Yang et al., 2004) into the HindIII/Klenow/
BglII-treated RSV-rabbit-b-globin plasmid (Gorman et al., 1983). The resulting
plasmid RSV-Env was treated with NdeI/HpaI to excise the RSV/Env/SV40-
polyA expression unit. This expression unit was then cloned into EcoRI/Kle-
now/NdeI-digested mPGK/S or mPGK/GP to make the double expression
vectors. Protein expression was confirmed by western blot analysis.
The plasmids encoding HA or myc inserted into Env were prepared in the
RSV-Env plasmid described above. The epitopes were inserted using the
PCR-based QuikChange site-directed mutagenesis kit (Stratagene, La Jolla,
CA) according to the manufacturer’s instructions for tag insertion into the V1
region of Env. The resulting amino acid sequence for HA-Env plasmid at the
V1 region was NLTSSYPYDVPDYAGIKNCSF. The resulting amino acid
sequence for myc-Env plasmid at the V1 region was NLTSSEQKLISEE-
DLIKNCSF. The sequences of both plasmids were confirmed by double-
strand DNA sequencing.
Antibodies
Anti-HIV type 1 (HIV-1) human monoclonal antibody 2F5, 2G12, and human
HIV immunoglobulin G (HIV IgG) were obtained from the AIDS Research and
Reference Reagent Program, Division of AIDS, National Institute of Allergy
and Infectious Diseases, National Institutes of Health. Mouse anti-CD3
(12F6) was provided by Johnson Wong (Massachusetts General Hospital,
Boston, MA). Rabbit anti-sGP/GP and anti-GPmonoclonal antibody (MAb149)
were provided by Anthony Sanchez (CDC). Human anti-GP antibody (KZ52)
and human anti-SARS-S monoclonal antibody were provided by Dennis Bur-
ton and Antonio Lanzavecchia, respectively. 13C6 monoclonal antibody to
Ebola GP was made available through USAMRIID (Frederick, MD). Rabbit
anti-HIV-Env and Gag were obtained from Advanced Biotechnologies (Colum-
bia, MD). Rabbit anti-HA tag and mouse anti-myc tag were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). Mouse anti-SARS-S and rabbit
anti-SARS-S antibody were generated in house and purchased from Imgenex
(San Diego, CA), respectively.
Cell Lines
Human embryonic kidney 293T cells and human kidney adenocarcinoma
786-O were purchased from the American Type Culture Collection and
maintained in Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad,
California) containing 10% fetal bovine serum (FBS) and 100 mg of penicillin-
streptomycin/ml. The human T cell leukemia cell line MT-2 and the HeLa-
derived cell line MAGI-CCR5 were obtained from the AIDS Research and
Reference Reagent Program.
Western Blot Analysis
Virus supernatant was mixed with 43 sample loading buffer (100 mM Tris, 4%
SDS, 20% glycerol, 5% 2-mercaptoethanol, 0.2% bromophenol blue) and
boiled for 5 min. The sample was then resolved by 4–15% gradient
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The membrane was blocked twice with Tris-buffered saline containing 0.05%
Triton X-100 (Sigma-Aldrich, St. Louis, MO) at room temperature for 5 min, fol-
lowed by incubation with the appropriate antibody (human HIV Ig, 1:5000;
KZ52, 1:10000; rabbit anti-Gag, 1:4000) in blocking buffer with 2% skim milk
for 1.5 hr at room temperature. The membrane was washed twice with 50 ml
of blocking buffer, followed by incubation with secondary antibody conjugated
with horseradish peroxidase (Santa Cruz Biotech; 1:5,000) for 30 min at room
temperature. After two washes with 50 ml of blocking buffer, the membrane
was developed using ECLwestern blotting detection reagents (GEHealthcare,
Piscataway, NJ) and was exposed on BiomaxMR film (Kodak, Rochester, NY).
Generation of Replication-Defective Pseudotyped Lentiviral Vectors
Pseudotyped lentiviral vectors with Env and GP were prepared according to
published methods (Yang et al., 2004). Briefly, the packaging vector
pCMVDR8.2, pHR0-CMV-Luciferase, and the envelope-expressing vector
were transiently cotransfected into 293T cells by use of calcium phosphate
reagent (Promega, Madison, WI). The amount of plasmid DNA used for making
different pseudotyped vectors was as follows: for lentiviral vectors, 7 mg of
pCMVDR8.2 plus 7 mg of pHR0-CMV-Luc and 10 mg of VR1012/Ebola-GP/
HIV-Env89.6P. Cells were transfected overnight, and replenished with fresh
medium. Supernatants were harvested 60 hr after transfection, filtered, and
stored at 80C. The same amount of virus, as determined by p24 ELISA as-
say (Beckman Coulter, Fullerton, CA), was added onto MT-2 (HIV target) and
786-O (Ebola-GP target) cells. The cells were harvested 48 hr after onset of in-
cubation and lysed in cell culture lysis buffer (Promega). The luciferase assay
was performed according to themanufacturer’s recommendations (Promega).
Buoyant Density Gradient Analysis of Pseudotyped
Lentiviral Vectors
Pseudotyped lentiviral vectors were prepared as mentioned in 293T cells.
Sixty hours after transfection, the supernatants were harvested and filtered
through a 0.45-mm syringe filter. The recombinant virus was first concentrated
by layering a 10 ml sample in tissue culture media onto 2.5 ml of Optiprep
(Iodixanol, 60% solution) (Accurate Biochemicals, Westbury, NY) and centri-
fuged at 53,0003 g for 1 hr in a Sorvall TH-641 rotor (Thermo Fisher Scientific,
Waltham, MA). The top 7.5 ml of supernatant was removed, and the remaining
solution was mixed uniformly to achieve a final concentration of 30%Optiprep
in a 5 ml final volume. The gradient was formed by centrifugation at 363,0003
g for 3.5 hr with a Beckman NVT-100 rotor.
HIV Infection of MAGI-CCR5 and Activated Human CD4+ T Cells
Human peripheral blood CD4+ T cells were isolated from elutriated lympho-
cytes from a healthy adult donor at the Transfusion Medicine Department of
Warren Grant Magnuson Clinical Center, National Institutes of Health,
Bethesda, MD. CD4+ T cells were isolated from the lymphocyte fraction by
depletion of non-CD4+ T cells with a CD4+ T cell isolation kit (Miltenyi Biotech,
Auburn, CA). The enriched CD4+ T cells were stimulated with 12F6 (anti-CD3)
and anti-CD28 (BD PharMingen) at 2 ng/106 cells/ml each in the RPMI 1640
medium supplemented with 10% fetal bovine serum, penicillin, and strepto-
mycin. After 48 hr, replication competent HIV-1 89.6 at 100 ng/ml of p24
was added to the culture. MAGI-CCR5 cells were plated on the chamber slide
(Lab-Tek) and HIV-1 89.6 at 50 ng/ml was added to the culture. Forty-eight
hours later, the cells were stained for confocal microscopy.
Confocal Microscopy
After transfection or infection, cells were washed with PBS and then fixed and
permeabilized for 30 min using Cytofix/Cytoperm solution (BD Biosciences).
The cells were then stained with specific first antibody against the envelope
and gag proteins (2G12 at 0.5 mg/ml, 13C6 at 0.1 mg/ml, rabbit-anti-HA at
1:100, and mouse-anti-myc at 1:500 and rabbit-anti-Gag at 1:4000) at room
temperature. After 1 hr, the cells were washed twice with PBS, followed by
incubation with secondary antibody conjugated with Alexa Fluor (Invitrogen)
(1 mg/ml) for 30 min at room temperature. The cells were washed twice with
PBS and then stained for the nuclei using DAPI in mounting medium (Santa
Cruz Biotech). Enriched human CD4 T cells were deposited onto a glass slide
using Cytospin (Thermo Fisher) before DAPI staining and mounting. Images of
stained cells were obtained by confocal microscopy (Leica SP2, LeicaMicrosystems, Exton, PA) using a 633 oil immersion objective NA 1.4. All
data were processed with Huygens Essential software for deconvolution
(Version 3.0, Scientific Volume Imaging BV, Hilversum, The Netherlands).
Sequential Z sections of stained cells were also recorded for 3D reconstruction
and iso-surface modeling of representative cells with Imaris software (version
5.7, Bitplane AG, Zurich, Switzerland). To investigate colocalization in a cellular
region, we used contour and channel masking techniques in the Imaris soft-
ware package to create precise 3D regions of interest (ROI) for cytoplasm
and membrane regions in 3D reconstructed confocal images of the cells
(Figure S4). The channel masking technique was then used in conjunction
with automatic thresholding to calculate colocalization statistics in the cyto-
plasm and membrane respectively. The fraction of one channel volume colo-
calized with another channel volume, and the Pearson channel correlation in
colocalized volume was calculated for cytoplasm, plasma membrane, and
whole cell using Imaris software colocalization package. Automatic threshold-
ing performed on channels selected for colocalization analysis in Imaris is
based on an algorithm developed by Costes and Lockett at NIH (Costes
et al., 2002). This algorithm was based on the exclusion of intensity pairs
that exhibit no correlation (Pearson’s correlation below zero). The same
thresholding was applied to each data set.
SUPPLEMENTAL DATA
The Supplemental Data include four supplemental figures and two supple-
mental movies and can be found with this article online at http://www.
cellhostandmicrobe.com/cgi/content/full/3/5/285/DC1/.
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